Enhanced CD45 expression is associated with the increased risk of relapse in B- or T-ALL [44], and the dependency of CD45 expression on HSP90α could serve as a predictive biomarker for evaluating the effectiveness of HSP90α inhibition [45]. This evidence concerns the gene HSP90AA1 and acute lymphoblastic leukemia.